Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

According to doctors, most men may be less likely to report symptoms due to embarrassment. Also, a few age-related prostate issues result in overactive bladder symptoms for men – who think it is ...

While it is clear that men with lower urinary ... inability to differentiate between symptoms attributable to detrusor overactivity (DO) and those caused by bladder-outlet obstruction (BOO ...

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

Discover how cold weather can trigger prostate problems in men over 60, including frequent urination, hormonal changes, and ...

Gemtesa is approved for men with overactive bladder symptoms who are receiving pharmacologic treatment for benign prostatic hyperplasia.

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur. Urol. 55 , 472–479 (2009).

The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive bladder (OAB ... milestone for the men with unresolved symptoms of OAB while being ...

Conclusions: Tolterodine 2mg twice daily is effective against all the troublesome symptoms of overactive bladder and these effects are meaningful to patients. Tolterodine was well tolerated.

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...